Greywolf Therapeutics
Emma Johnson possesses extensive experience in the life sciences investment sector, currently serving as a Board Observer at Purespring Therapeutics and a Board Member at Tenpoint Therapeutics Ltd, Epsilogen Ltd, Nucleome Therapeutics, and Grey Wolf Therapeutics. As a Senior Investment Manager at British Patient Capital, Emma leads investments in standout UK life sciences companies, managing fund reporting, deal origination, execution, and portfolio management. Emma's previous role as an Investment Associate at Catapult Ventures Group involved overseeing a diverse portfolio of companies and supporting innovative projects in digital health and biotechnology. Emma holds a Master of Science in Cognitive Neuroscience from UCL and a Bachelor of Science in Neuroscience from the University of Bristol.
This person is not in the org chart
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.